問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Radiation Therapy

Division of Urology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

林哲弘Lin, Che-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

  • windsun@gmail.com

Recruiting Trial

179Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林哲弘

List

278Cases

2020-08-01 - 2024-11-29

Phase I

A Phase I Study of GNX102 in patients with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    GNX102

Participate Sites
2Sites

Recruiting2Sites

2017-05-09 - 2018-04-22

Phase I/II

A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Newly Diagnosed Acute Myeloid Leukemia

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Ulocuplumab (BMS-936564)

Participate Sites
6Sites

Terminated5Sites

2020-04-01 - 2024-01-10

Phase III

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Metastatic Castration-resistant Prostate Cancer

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mL

Participate Sites
6Sites

Recruiting6Sites

2021-09-24 - 2022-12-28

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2017-08-01 - 2022-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated7Sites

2019-03-01 - 2021-12-31

Phase I

A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer

  • Condition/Disease

    Gastric, Colorectal, Pancreatic or Biliary Cancer

  • Test Drug

    AbGn-107

Participate Sites
3Sites

Terminated3Sites

2014-07-01 - 2021-11-30

Phase II

A Phase 2, Randomized, Double-blind Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase

  • Condition/Disease

    Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

  • Test Drug

    Momelotinib

Participate Sites
7Sites

Terminated6Sites

2022-09-30 - 2025-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

1 24 25 26 27 28
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB